Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia.

J Pediatr Hematol Oncol

Hospices Civils de Lyon, Hôpital Debrousse, Service d'Onco-Hématologie Pédiatrique, Lyon, France.

Published: October 2005

Acquired Glanzmann's thrombasthenia is an uncommon event in association with leukemia. The authors describe a patient with acute lymphoblastic leukemia (ALL) who presented with severe hemorrhagic syndrome, without disseminated intravascular coagulation. The patient's course was complicated by the occurrence of severe hemorrhagic episodes, with a thrombasthenia-like profile, requiring multiple transfusions with packed red cells, platelets, and fresh-frozen plasma. Biological explorations detected anti-GPIIb/IIIa complex antibodies. The patient finally died with refractory disease and persistent bleeding. This case is the first reported of autoantibodies to GPIIb/IIIa in ALL. Such paraneoplastic syndrome is potentially responsible for severe life-threatening hemorrhage.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mph.0000183864.56533.d2DOI Listing

Publication Analysis

Top Keywords

acquired glanzmann's
8
glanzmann's thrombasthenia
8
acute lymphoblastic
8
lymphoblastic leukemia
8
severe hemorrhagic
8
thrombasthenia associated
4
associated acute
4
leukemia acquired
4
thrombasthenia uncommon
4
uncommon event
4

Similar Publications

Glanzmann Thrombasthenia (GT) is an inherited platelet disorder caused by defects in platelet integrin αβ (GPIIb/IIIa), which is a platelet receptor essential for the binding of fibrinogen. This can lead to severe bleeding, especially after trauma or perioperatively, and to microcytic anemia because of chronic blood loss. We report on a 40-year-old female patient with extensive bleeding complications and platelet antibody formation who presented in Homburg and Freiburg for extensive platelet function analyses and molecular genetic analyses.

View Article and Find Full Text PDF

Glanzmann thrombasthenia (GT) is a rare platelet disorder characterized by qualitative/quantitative deficiencies of the platelets' fibrinogen receptor, glycoprotein (GP) IIb/IIIa complex, resulting in impaired platelet aggregation and increased bleeding time. Most cases are hereditary with an autosomal recessive pattern of inheritance, but acquired GT also occurs. We report the surgical management of symptomatic chronic subdural hematoma (CSDH), a rare condition in young individuals, in a 37-year-old man who had GT and a history of mild head trauma approximately one month before admission.

View Article and Find Full Text PDF
Article Synopsis
  • rFVIIa is a human recombinant activated coagulation factor VII used for over two decades to treat and prevent bleeding in various bleeding disorders, including congenital and acquired hemophilia, congenital factor VII deficiency, and Glanzmann thrombasthenia.
  • Its dosage, administration, and indications vary between the US, Europe, and Japan based on patient needs and regulatory practices.
  • Despite the emergence of new therapies like emicizumab for hemophilia A, rFVIIa remains crucial for managing bleeding episodes, especially in surgical situations and when other treatments fail.
View Article and Find Full Text PDF

Introduction Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder of platelets caused by a deficiency in the glycoprotein IIb-IIIa. Bleeding from the skin, mucous membranes, and ecchymosis are symptoms manifested starting in early childhood. There may also be major bleeding conditions as a result of surgical procedures or trauma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!